Abstract
This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
MeSH terms
-
Amidohydrolases / antagonists & inhibitors*
-
Amidohydrolases / metabolism
-
Brain / drug effects*
-
Brain / physiopathology
-
Brain Death
-
Brain Diseases / chemically induced*
-
Brain Diseases / mortality
-
Brain Diseases / physiopathology
-
Clinical Trials, Phase I as Topic
-
Coma / chemically induced
-
Coma / mortality
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Early Termination of Clinical Trials
-
Enzyme Inhibitors / adverse effects*
-
Humans
-
Risk Assessment
-
Risk Factors
-
Treatment Outcome
Substances
-
Enzyme Inhibitors
-
Amidohydrolases
-
fatty-acid amide hydrolase